$3.69+0.05 (+1.37%)
Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals, Inc. in the Healthcare sector is trading at $3.69. The stock is currently 20% below its 52-week high of $4.60, remaining 41.4% above its 200-day moving average. Technical signals show neutral RSI of 61 and bearish MACD signal, explaining why ELDN maintains its current momentum and trend strength. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It uses its immunology expertise in targeting the CD40 Ligand (CD40L) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amy...
NewcelX Ltd. reported its 2025 financial results, with leadership emphasizing a "transformative year" marked by merger completion, balance sheet improvements, and progress in its lead Type 1 diabetes program, NCEL-101. Ronen Twito, executive chairman and CEO, said the company is positioning NCEL-101, developed in partnership with Eledon Pharmaceuticals Inc., as its primary long-term value driver. Twito added that the company's stem cell-derived islet platform, combined with targeted immune prote
Eledon Pharmaceuticals Inc. (NASDAQ:ELDN) is one of the 10 Unstoppable Stocks That Could Double Your Money. Eledon Pharmaceuticals Inc. (NASDAQ:ELDN) is one of the unstoppable stocks that could double your money. On March 19, Eledon reported its financial results for the full year 2025, highlighting the clinical advancement of its anti-CD40L antibody, tegoprubart. The company […]
Eledon Pharmaceuticals (NASDAQ:ELDN) used a presentation at the Leerink Partners Global Healthcare Conference to highlight what CEO David-Alexandre Gros described as a rapid expansion in clinical experience with its lead CD40 ligand antibody, tegoprubart, across multiple transplant settings. Gros sa
The partnership draws on clinical experience from over 100 transplant patients treated with tegoprubart.
Eledon Pharmaceuticals (NASDAQ:ELDN) executives discussed recent clinical results and upcoming regulatory plans for its investigational immunosuppressive therapy, referred to in the discussion as “tego,” highlighting data from the company’s Phase II BESTOW kidney transplant study, longer-term follow